RxDoctor Payments DataLook up a doctor →

Hemant Pandey, MD

Neurology · Chandler, AZNPI 1275535403

Payments from drug & device makers

$6,192,526in general payments, 2019–2025

Across 1,265 payments — averaging $4895.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$4.1M
  • Eisai Inc.$402K
  • Novartis$391K
  • E.r. Squibb & Sons, L.L.C.$340K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$248K
  • Biohaven Pharmaceuticals, Inc.$136K
  • plus $596K from 54 others
$47,552in research payments, 2019–2025

Across 6 payments — averaging $7925.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$47K
  • Lundbeck LLC$86

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly30$4,079,933
Eisai Inc.309$402,016
Novartis24$390,611
E.r. Squibb & Sons, L.L.C.7$340,326
Otsuka Pharmaceutical Development & Commercialization, Inc.16$247,862
Biohaven Pharmaceuticals, Inc.34$135,715
Ipsen Innovation59$131,334
UCB SA13$126,507
H. Lundbeck A S31$91,375
AbbVie(2 entities)174$90,118
Lilly USA, LLC61$30,453
Lexicon Pharmaceuticals, Inc.4$30,117
Novo Nordisk AS6$28,029
Biohaven Pharmaceutical Holding Company Ltd.11$20,448
C2n Diagnostics, LLC44$18,374
Boston Scientific14$11,080
Avanir Pharmaceuticals, Inc.7$9,758
UCB, Inc.72$1,138
AstraZeneca(2 entities)17$425
Jazz Pharmaceuticals Inc.11$423
Biogen18$388
MDD US Operations, LLC19$382
Inspire Medical Systems, Inc.15$378
Neurocrine Biosciences, Inc.17$367
Amgen(2 entities)19$356
Argenx US, Inc.18$346
Bristol Myers Squibb17$264
Lundbeck LLC11$256
Sanofi11$251
Sunovion Pharmaceuticals Inc.15$242
Amneal Pharmaceuticals LLC13$232
Mallinckrodt Hospital Products Inc.10$220
Pfizer12$202
Novo Nordisk2$171
EMD Serono, Inc.11$164
Grifols USA, LLC8$145
Otsuka America Pharmaceutical, Inc.7$144
Acadia Pharmaceuticals Inc6$134
SK Life Science, Inc.6$129
CSL Behring4$121
Teva Pharmaceuticals USA, Inc.6$119
Harmony Biosciences LLC4$114
Neurelis, Inc.5$113
Takeda Pharmaceuticals U.S.A., Inc.4$85
Genentech USA, Inc.3$77
Alnylam Pharmaceuticals Inc.4$73
Akcea Therapeutics, Inc.2$62
TG Therapeutics, Inc.3$60
Impel Pharmaceuticals Inc.3$57
GE HealthCare3$55
Supernus Pharmaceuticals, Inc.3$49
Mallinckrodt Enterprises LLC2$48
Abbott2$46
Acorda Therapeutics, Inc3$43
Upsher-smith Laboratories LLC2$42
Sumitomo Pharma America, Inc.5$36
Medtronic2$35
Octapharma USA, Inc.1$30
Avid Radiopharmaceuticals, Inc.1$28
Livanova USA, Inc.2$27

How this compares

$6,192,526 in reported general payments places this provider in the 95th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona →

Medicare billing

Part B allowed, 2024
$832,493
Medicare patients
1,127
Services billed
9,189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Chandler

See the full list for Arizona →

Where these figures come from

Is this you, or does something look wrong? →